Trading Update

17 July 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today provides a trading update for the financial year ending 30 September 2025.

The Company anticipates revenues to be at least £6.3 million, ahead of expectations and representing a 9% increase on 2024 revenues, thereby solidifying its stated return to growth. Further, it is expected that this revenue growth will continue into 2026, moving the Company towards medium term profitability.

IXICO has seen positive sales momentum driven by the implementation of the Company's 'Innovate Lead Scale' strategy, which has seen IXICO deliver scientific innovation while expanding commercial and geographic reach in key therapeutic areas and new market verticals. As indicated in the Half-year Trading Update on 16 April 2025, the Company has therefore increased the expected investment in 2025 to drive revenue growth in 2026 and beyond.

The Company expects to hold cash of at least £3.0 million at the end of the financial year.

Final results for the year ending 30 September 2025 will be announced in December 2025.

Bram Goorden, CEO of IXICO, said: "The Innovate Lead Scale strategy outlined during our capital raise has begun to deliver results. The positive momentum is a result of a team approach, executing with discipline to grow revenues, expand market share and diversify the neurological therapeutic areas we operate in. In addition, we are rapidly advancing our technology platform offering with new differentiated biomarker analytics products and applications fit for scale. This activity strengthens my belief that we will continue to build upon this year's commercial success and the progress we are making towards profitability in the medium term".